Risk factors cardiovascular autonomic neuropathy in type 1 diabetes mellitus

Authors

  • Stepura О. Р. L. Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine; Center for Innovative Medical Technologies, Kyiv, Ukraine
  • Shekera O. Р. L. Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • Mankovsky B. Р. L. Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine;Center for Innovative Medical Technologies, Kyiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2019.2.09

Keywords:

diabetes mellitus type 1, cardiac autonomic neuropathy, cardiovascular reflex tests, heart rate variability.

Abstract

Cardiac autonomic neuropathy (CAN) is frequent, life-threatening complications of diabetes mellitus (DM), increasing the mortality and cardiovascular morbidity in diabetes mellitus patients.

The article describes the prevalence, relationship and risk factors of CAN in patients with type 1 diabetes mellitus. We included 23 patients with type 1 diabetes and 17 healthy patients. Using the cardiovascular reflex Ewing tests, which are the «golden» standard for the diagnosis of CAN, we investigated the time-domain and spectral parameters of heart rate variability (HRV). Patients with type 1 diabetes had a statistically signifi­cant decrease in the parameters of time-domain and spectral analysis of HRV and high LF/HF ratio during spectral analysis, indicating an increase in the tone of the sympathetic autonomic nervous system and a de­crease in the autonomic parasympathetic department nervous system. Using linear regression analysis, it was revealed that the age of patients plays a role in the development of CAN in patients with type 1 diabetes and the glycosylated hemoglobin was correlated only with the sympathetic-parasympathetic coefficient. We did not find the relationship of the CAN with distal symmetrical polyneuropathy, retinopathy and diabetic kidney disease.

References

Sokolova LK. Liky Ukrai'ny 2011; 6(152): 31-35.

Pop-Busui R, Evans GW, Gerstein HC, et al. Diabetes Care 2010; 33 (7): 1578-1584. https://doi.org/10.2337/dc10-0125.

Soedamah-Muthu SS, Chaturvedi N, Witte DR, et al. Diabetes Care 2008; 31 (7): 1360-1366. https://doi.org/10.2337/dc08-0107.

Wackers FJ, Young LH, Inzucchi SE, et al. Diabetes Care 2004; 27 (8): 1954-1961.

Pop-Busui R, Boulton A, et al. Diabetes Care 2017; 40 (1): 136-154. https://doi.org/10.2337/dc16-2042.

Serhiyenko V, Serhiyenko A. World J Diabetes 2018; 9 (1): 1-24. https://doi.org/10.4239/wjd.v9.i1.1.

Pop-Busui R, Martin C, Herman WH, Braffett BH. Diabetes Care 2017; 40: 94-100. https://doi.org/10.2337/dc16-1397.

Mogensen UM, Jensen T, Kober L, et al. Diabetes 2012; 61 (7): 1822-1830. https://doi.org/10.2337/db11-1235.

Ziegler D, Behler M, Schroers-Teuber M, et al. BMJ Open 2015;5: e006559. https://doi.org/10.1136/bmjopen-2014-006559.

Orlov S, Cherney DZ, Pop-Busui R, et al. Clin J Am Soc Nephrol 2015; 10 (7): 1136-1144. https://doi.org/10.2215/CJN.11441114.

Fisher VL, Tahrani AA, et al. Diabetes, metabolic syndrome and obesity: targets and therapy 2017; 10: 419-434. https://doi.org/10.2147/DMSO.S129797.

Downloads

Published

2021-06-30

How to Cite

Степура, О. А., Шекера, О. Г., & Маньковський, Б. (2021). Risk factors cardiovascular autonomic neuropathy in type 1 diabetes mellitus. Problems of Endocrine Pathology, 68(2), 60-65. https://doi.org/10.21856/j-PEP.2019.2.09

Issue

Section

CLINICAL ENDOCRINOLOGY